Patent ID: 9265798
Filing Date: 2016-02-23
CPC Classification: A61K,A61L,A61M

Claim Text:
1. A method of treating a cardiovascular disorder in a subject, comprising: providing an extracellular matrix (ECM) composition comprising acellular bioremodelable mesothelial tissue, said mesothelial tissue comprising endogenous proteoglycans, transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) that collectively induce myofibroblast and stem cell migration, and differentiation of said stem cells into cardiomyocytes when administered to damaged cardiovascular tissue; providing a mechanical circulatory support (MSC) device that is configured to support ventricular function of a mammalian heart when connected thereto; connecting said MSC device to said subject's circulatory system; administering said ECM composition proximate damaged cardiovascular tissue of said subject's heart, wherein said ECM composition induces neovascularization and bioremodeling of said subject's damaged cardiovascular tissue; and providing support of ventricular function of said subject's heart with said MSC device.